Fosun Pharmaceutical announced that recently, its holding subsidiary Fosun Pharmaceutical Co., Ltd., the drug registration application for levosalbutamol hydrochloride atomized inhalation solution was approved by the State Drug Administration. The approved indications are to treat or prevent bronchospasm associated with adults and children aged 6 and above. The drug was independently developed by the Group, with a cumulative R&D investment of about 5.66 million yuan as of June 2026. In 2025, the drug's domestic sales volume was about 73 million yuan. The approved listing will enrich the Group's product line, but the sales situation is uncertain.

Fosun Pharmaceutical announced that recently, its holding subsidiary Fosun Pharmaceutical Co., Ltd., the drug registration application for levosalbutamol hydrochloride atomized inhalation solution was approved by the State Drug Administration. The approved indications are to treat or prevent bronchospasm associated with adults and children aged 6 and above. The drug was independently developed by the Group, with a cumulative R&D investment of about 5.66 million yuan as of June 2026. In 2025, the drug's domestic sales volume was about 73 million yuan. The approved listing will enrich the Group's product line, but the sales situation is uncertain.